Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The Austrian Immunoglobulin in MS (AIMS) study: final analysis.

S Strasser-Fuchs1, F Fazekas, F Deisenhammer

  • 1Department of Neurology, Karl-Franzens University, Graz, Austria.

Multiple Sclerosis (Houndmills, Basingstoke, England)
|February 24, 2001
PubMed
Summary

Intravenous immunoglobulin (IVIG) therapy shows promise for relapsing-remitting multiple sclerosis (MS). Monthly IVIG treatments over two years significantly reduced disability progression and relapse frequency in MS patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Value of treatment by comprehensive stroke services for the reduction of critical gaps in acute stroke care in Europe.

European journal of neurology·2020
Same author

Correction to: Features of intracranial hemorrhage in cerebral venous thrombosis.

Journal of neurology·2020
Same author

Features of intracranial hemorrhage in cerebral venous thrombosis.

Journal of neurology·2020
Same author

Guillain-Barré syndrome in a patient with antibodies against SARS-COV-2.

European journal of neurology·2020
Same author

The European Academy of Neurology is 6 years old: challenges, opportunities and strategic priorities for the future.

European journal of neurology·2020
Same author

Ventilation time and prognosis after stroke thrombectomy: the shorter, the better!

European journal of neurology·2020

Area of Science:

  • Neurology
  • Immunology
  • Clinical Trials

Background:

  • Observational studies and positive experiences in other autoimmune disorders suggest potential benefits of intravenous immunoglobulin (IVIG) for multiple sclerosis (MS).
  • The efficacy of IVIG as an interval treatment for MS has not been rigorously evaluated in randomized controlled trials.

Purpose of the Study:

  • To investigate the effectiveness of monthly IVIG treatment in patients with relapsing-remitting MS.
  • To assess the impact of IVIG on disability progression, relapse frequency, and daily living in MS patients.

Main Methods:

  • A randomized, double-blind, placebo-controlled trial (Austrian Immunoglobulin in Multiple Sclerosis - AIMS study) involving 148 patients with relapsing-remitting MS.
  • Patients received monthly IVIG (0.15-0.2 g/kg bodyweight) or placebo for 2 years.

Related Experiment Videos

  • Outcomes measured included Expanded Disability Status Scale (EDSS), relapse frequency, and patient-reported scales (Incapacity Status and Environmental Status Scales).

    • Main Results:

    • IVIG treatment was associated with a significantly more favorable course of disability (EDSS change: -0.23 vs 0.12; P=0.008).
    • A significant reduction in relapse frequency was observed in the IVIG group (0.52 vs 1.26; P=0.011).
    • Beneficial effects were noted within 6 months and did not depend on baseline disability severity. Patient-reported outcomes on daily and social living also improved.

    Conclusions:

    • IVIG is a potential alternative treatment option for relapsing-remitting MS.
    • Further research is warranted to determine the optimal usage and long-term benefits of IVIG for MS.
    • IVIG demonstrated positive effects on disability, relapse rates, and quality of life in MS patients.